The steering body, the European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH), oversees the work programme carried out by the Committee of Experts on minimising the public health risks posed by counterfeiting of medical products and related crimes (CD-P-PH/CMED)
The primary responsibilities the European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH), according to the terms of reference adopted by the Committee of Ministers, are as follows:
- Fulfilling the tasks of the Public Health Committee set out in the Convention on the Elaboration of a European Pharmacopoeia, as amended by Articles 2(a), 3 and 4, of the Protocol European Treaty Series No. 134 and in Resolution Res AP (2007)1 on the classification of medicines as regards their supply;
- Contributing to improving public healthcare through harmonising provisions and practices related to pharmaceuticals in Europe;
- Minimising the public health risks posed by counterfeit medicines and similar crimes through multisectorial prevention and risk management strategies and through supporting the elaboration and implementation of relevant national and international legislation;
- Ensuring and monitoring adequate follow-up of the results of the relevant activities of the Council of Europe and of member states party to the Partial Agreement in the Social and Public Health field.
View the full terms of reference.
The Committee of Experts on minimising the public health risks posed by counterfeiting of medical products and related crimes (CD-P-PH/CMED) is entrusted with developing and promoting the implementation of multisectoral risk prevention and management strategies
Mission of the Committee of Experts on Minimising Public Health Risks Posed by Falsification of Medical Products and Similar Crimes (CD-P-PH/CMED).
Its primary responsibilities, according to the terms of reference, are as follows:
- developing and promoting the implementation of multisectorial risk prevention and management strategies, e.g. programmes and model approaches in the field of public health protection from falsified medical products and similar crimes;
- facilitating networking and co-operation within member states through activities promoting recognised networking models (e.g. the model for a network of SPOCs prepared by the former Ad hoc Group on counterfeit medicines);
- providing public health authorities with strategies for risk communication on falsified medical products and related crimes;
- maintaining and developing further a specific multisectorial expertise with a view to adapting programmes and procedures to the rapidly changing patterns of crime involving healthcare products;
- promoting a favourable environment for the implementation of regional and international specific legal instruments in this field at the national and international level;
- developing support tools for information exchange on management, prevention and follow-up of the risks posed by such crimes.
The composition and project approach of the Committee is multisectorial, bringing together healthcare and law enforcement officials from Council of Europe Member States, European institutions, pharmaceutical industries and trade, and international organisations.
View the full terms of reference.
The term "counterfeiting" as used in the Medicrime Convention is meant in its broadest sense of "falsification".